Niraparib Maintenance Therapy for Ovarian Cancer

Описание к видео Niraparib Maintenance Therapy for Ovarian Cancer

Panelists Bradley J. Monk, MD; Angeles Alvarez Secord, MD; Robert L. Coleman, MD; Thomas Herzog, MD; and Kathleen N. Moore, MD, outline the clinical evidence for the use of the PARP inhibitor, niraparib, in advanced ovarian cancer.

Комментарии

Информация по комментариям в разработке